Angeborene Antikörpermangelsyndrome („B-Zell-Defekte“)

Zusammenfassung

Patienten jedweden Alters sollten bei Vorliegen einer pathologischen Infektanfälligkeit (z. B. häufige bakterielle Infektionen des Respirationstraktes) auf das Vorliegen eines angeborenen Antikörpermangelsyndroms untersucht werden. Die frühe Diagnose einer primären Antikörperdefizienz ist entscheidend für die Prognose der betroffenen Patienten, da nur durch frühzeitigen Beginn einer adäquat dosierten Immunglobulin-Substitutionstherapie die Häufigkeit infektiöser Episoden reduziert und damit eine annähernd normale Lebensqualität ermöglicht wird. Durch frühe Diagnose und Therapie wird insbesondere die Entwicklung von Langzeitfolgen wie chronisch-obstruktiven Lungenerkrankungen verhindert.

Summary

Patients at any age with undue susceptibility to infections (e. g. recurrent bacterial infections of the upper and lower respiratory tract) should be investigated for possible primary antibody deficiency syndrome. Early diagnosis of inborn defects of antibody production is pivotal for the prognosis of the patients, as the frequency and severity of infectious episodes and their complications can only be reduced by early initiation and sufficient dosage of immunoglobulin substitution therapy. Therapy can be provided by intravenous infusions or subcutaneous home treatment. Late diagnosis and delayed treatment of the severe antibody deficiency syndromes such as CVID results in substantial morbidity and considerable mortality.

Schlüsselwörter

Antikörpermangelsyndrom - Antikörperdefizienz - Hypogammaglobulinämie

Keywords

Immunodeficiency - antibody deficiency - hypogammaglobulinemia

• Literatur

• 1 Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol 2007; 27: 497-502.
• 2 Bruton OC. Agammaglobulinemia. Pediatrics 1952; 9: 722-728.
• 3 Burrows PD, Cooper MD. IgA deficiency. Adv Immunol 1997; 65: 245-276.
• 4 Castigli E, Wilson SA, Garibyan L. et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005; 37: 829-834.
• 5 Conley ME, Mathias D, Treadaway J. et al. Mutations in Btk in patients with presumed X-linked agammaglobulinemia. Am J Hum Genet 1998; 62: 1034-1043.
• 6 Conley M, Rohrer J, Rapalus L. et al. Defects in early B-cell development: comparing the consequences of abnormalities in pre-BCR signalling in the human and the mouse. Immunol Rev 2000; 178: 75-90.
• 7 Conley ME, Howard V. Clinical findings leading to the diagnosis of X-linked agammaglobulinemia. J Pediatr 2002; 141: 566-571.
• 8 Dalal I, Reid B, Nisbet-Brown E, Roifman CM. The outcome of patients with hypogammaglobulinemia in infancy and early childhood. J Pediatr 1998; 133: 144-146.
• 9 Durandy A, Revy P, Fischer A. Hyper-immunglobulin- M syndromes caused by an intrinsic B cell defect. Curr Opin Allergy Clin Immunol 2003; 3: 421-425.
• 10 Gaspar HB, Lester T, Levinsky RJ, Kinnon C. Bruton’s tyrosine kinase expression and activity in X-linked agammaglobulinaemia (XLA): the use of protein analysis as a diagnostic indicator of XLA. Clin Exp Immunol 1998; 111: 334-338.
• 11 Geha RS, Notarangelo LD, Casanova JL. et al. International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2007; 120: 776-794.
• 12 Gulino AV, Notarangelo LD. Hyper IgM syndromes. Curr Opin Rheumatol 2003; 15: 422-429.
• 13 Grimbacher B, Hutloff A, Schlesier M. et al. Homozygous loss of ICOS is associated with adultonset common variable immunodeficiency. Nat Immunol 2003; 4: 261-268.
• 14 Hammarström L, Vorechovský I, Webster D. Selective IgA deficiency (SIgAD) and common variable immundeficiency (CVID). Clin Exp Immunol 2000; 120: 225-231.
• 15 Hermaszewski RA, Webster ADB. Primary hypogammaglobulinaemia: A survey of clinical manifestations and complications. Q J Med 1993; 8: 631-642.
• 16 Hubert A, Baumann U, Borte M. et al. Humorale Immundefizienz I: Antikörpermangelsyndrome ohne bekannten genetischen Defekt. Allergologie 2004; 27: 296-310.
• 17 Janeway CA, Apt L, Gitlin D. Agammaglobulinemia. Trans Assoc Am Physicians 1953; 66: 200-202.
• 18 Lederman HM, Winkelstein JA. X-linked agammaglobulinemia: An analysis of 96 patients. Medicine 1985; 64: 145-156.
• 19 Lindvall JM, Blomberg KE, Valiaho J. et al. Bruton ´s tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 2005; 203: 200-215.
• 20 Lopez Granados E, Porpiglia AS, Hogan MB. et al. Clinical and molecular analysis of patients with defects in micro heavy chain gene. J Clin Invest 2002; 110: 1029-1035.
• 21 McKinney Jr RE, Katz SL, Wilfert CM. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis 1987; 9: 334-356.
• 22 Meffre E, Milili M, Blanco-Betancourt C. et al. Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J Clin Invest 2001; 108: 879-886.
• 23 Minegishi Y, Rohrer J, Coustan-Smith E. et al. An essential role for BLNK in human B cell development. Science 1999; 286: 1954-1957.
• 24 Minegishi Y, Coustan-Smith E, Rapalus L. et al. Mutations in Igalpha (CD79a) result in a complete block in B-cell development. J Clin Invest 1999; 104: 1115-1121.
• 25 Minegishi Y, Coustan-Smith E, Wang YH. et al. Mutations in the human lambda5/14.1 gene result in B cell deficiency and agammaglobulinemia. J Exp Med 1998; 187: 71-77.
• 26 Nomura K, Kanegane H, Karasuyama H. et al. Genetic defect in human X-linked agammaglobulinemia impedes a maturational evolution of pro-B cells into a later stage of pre-B cells in the B-cell differentiation pathway. Blood 2000; 96: 610-617.
• 27 Pan Q, Hammarstrom L. Molecular basis of IgG subclass deficiency. Immunol Rev 2000; 178: 99-110.
• 28 Sadawa A, Takihara Y, Kim JY. et al. A congenital mutation of the novel gene LRRC8 causes agammaglobulinemia in humans. J Clin Invest 2003; 112: 1707-1713.
• 29 Salzer U, Chapel HM, Webster AD. et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005; 37: 820-828.
• 30 Smahi A, Courtois G, Rabia SH. et al. The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet 2002; 11: 2371-2375.
• 31 Stavnezer-Nordgren J, Kekish O, Zegers BJ. Molecular defects in a human immunoglobulin kappa chain deficiency. Science 1985; 230: 458-461.
• 32 van Zelm MC, Reisli I, van der Burg M. et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006; 354: 1901-1912.
• 33 Vetrie D, Vorechosvsky I, Sideras P. et al. The gene involved in X-linked agammaglobulinemia is a member of the src family of protein-tyrosine kinases. Nature 1993; 361: 226-233.
• 34 Warnatz K, Salzer U, Gutenburger S. et al. Finally found: human BAFF-R deficiency causes CVID.. XIth Meeting of the European Society for Immunode?. ciencies, October 2004
• 35 Wood P, Stanworth S, Burton J. et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol 2007; 149: 410-423.
• 36 Yel L, Minegishi Y, Coustan-Smith E. et al. Mutations in the mu heavy chain gene in patients with agammaglobulinemia. N Engl J Med 1996; 335: 1486-1493.